Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed

Future Medicinal Chemistry

Volumn 4, Issue 4, 2012, Pages 505-524

  Gryder, Berkley E ^a   Sodji, Quaovi H ^a   Oyelere, Adegboyega K ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACY 1215; AZITHROMYCIN; BORTEZOMIB; CLARITHROMYCIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; ROMIDEPSIN; UNCLASSIFIED DRUG; VORINOSTAT;

ANEMIA; CANCER THERAPY; CARDIOTOXICITY; CELL TYPE; CRYSTAL STRUCTURE; CUTANEOUS T CELL LYMPHOMA; DEHYDRATION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG SYNTHESIS; EPIGENETICS; HISTONE ACETYLATION; HUMAN; HYPOTENSION; INFECTION; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SEPSIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CHROMATIN; CLINICAL TRIALS AS TOPIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; PROTEIN ISOFORMS;

EID: 84858685501     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.3     Document Type: Review

References (145)

1. Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J. Natl Cancer Inst. 103(2), 117-128 (2011).
2. Sadikovic B, Al-Romaih K, Squire JA, Zielenska M. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr. Genomics 9(6), 394-408 (2008).
3. Huang YW, Kuo CT, Stoner K, Huang THY, Wang LS. An overview of epigenetics and chemoprevention. FEBS Lett. 585(13), 2129-2136 (2011).
4. Schulz WA, Hoffmann MJ. Transcription factor networks in embryonic stem cells and testicular cancer and the definition of epigenetics. Epigenetics 2(1), 37-42 (2007). (Pubitemid 46824848)
5. Jagannathan V, Robinson-Rechavi M. The challenge of modeling nuclear receptor regulatory networks in mammalian cells. Mol. Cell. Endocrinol. 334(1-2), 91-97 (2011).
6. Morris KV. Long antisense non-coding RNAs function to direct epigenetic complexes that regulate transcription in human cells. Epigenetics 4(5), 296-301 (2009).
7. Willingham AT, Gingeras TR. TUF love for 'junk' DNA.Cell 125(7), 1215-1220 (2006).
8. Fire AZ. Gene silencing by double-stranded RNA (Nobel lecture). Angew. Chem. Int. Ed. Engl. 46(37), 6967-6984 (2007).
9. Blackledge NP, Klose RJ. CpG island chromatin A platform for gene regulation. Epigenetics 6(2), 147-152 (2011).
10. Frederiks F, Stulemeijer IJE, Ovaa H, Van Leeuwen F. A modified epigenetics toolbox to study histone modifications on the nucleosome core. ChemBioChem 12(2), 308-313 (2011).
11. Gunjan A, Singh RK. Epigenetic therapy: targeting histones and their modifications in human disease. Future Med. Chem. 2(4), 543-548 (2010).
12. Cairns BR. The logic of chromatin architecture and remodelling at promoters. Nature 461(7261), 193-198 (2009).
13. Dorier J, Stasiak A. The role of transcription factories-mediated interchromosomal contacts in the organization of nuclear architecture. Nucleic Acids Res. 38(21), 7410-7421 (2010).
14. Lanctot C, Cheutin T, Cremer M, Cavalli G, Cremer T. Dynamic genome architecture in the nuclear space: regulation of gene expression in three dimensions. Nat. Rev. Genet. 8(2), 104-115 (2007). (Pubitemid 46122840)
15. Chapman-Rothe N, Brown R. Approaches to target the genome and its epigenome in cancer. Future Med. Chem. 1(8), 1481-1495 (2009).
16. Garber K. HDAC inhibitors overcome first hurdle. Nat. Biotechnol. 25(1), 17-19 (2007). (Pubitemid 46087886)
17. Nalabothula N, Carrier F. Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization. Epigenomics 3(2), 145-155 (2011).
18. Wang Z, Zang C, Cui K et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138(5), 1019-1031 (2009).
19. Bradner JE, West N, Grachan ML et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6(3), 238-243 (2010).
20. Lee JH, Hart SRL, Skalnik DG. Histone deacetylase activity is required for embryonic stem cell differentiation. Genesis 38(1), 32-38 (2004). (Pubitemid 38197607)
21. Brunmeir R, Lagger S, Seiser C. Histone deacetylase 1 and 2-controlled embryonic development and cell differentiation. Int. J. Dev. Biol. 53(2-3), 275-289 (2009).
22. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17(3), 330-339 (2011).
23. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7(10), 854-868 (2008).
24. Georgopoulos K. From immunity to tolerance through HDAC. Nat. Immunol. 10(1), 13-14 (2009).
25. Karpac J, Jasper H. Metabolic homeostasis: HDACs take center stage. Cell 145(4), 497-499 (2011).
26. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6(1), 38-51 (2006). (Pubitemid 43054973)
27. Verdin E, Dequiedt F, Kasler HG. Class 2 histone deacetylases: versatile regulators. Trends Genet. 19(5), 286-293 (2003). (Pubitemid 36507011)
28. Bieliauskas AV, Pflum MKH. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 37(7), 1402-1413 (2008).
29. Burton SG, Dorrington RA. Hydantoin-hydrolysing enzymes for the enantioselective production of amino acids: new insights and applications. Tetrahedron Asymmetry 15(18), 2737-2741 (2004). (Pubitemid 39277998)
30. Wang DF, Helquist P, Wiech NL, Wiest O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human Class 1 histone deacetylases. J. Med. Chem. 48(22), 6936-6947 (2005). (Pubitemid 41533115)
31. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132(31), 10842-10846 (2010).
32. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 26(9), 1351-1356 (2007). (Pubitemid 46328465)
33. Grant C, Rahman F, Piekarz R et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev. Anticancer Ther. 10(7), 997-1008 (2010).
34. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J. Med. Chem. 46(24), 5097-5116 (2003). (Pubitemid 37414179)
35. Mwakwari SC, Patil V, Guerrant W, Oyelere AK. Macrocyclic histone deacetylase inhibitors. Curr. Top. Med. Chem. 10(14), 1423-1440 (2010).
36. Patil V, Guerrant W, Chen PC et al. Anti-malarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. Bioorg. Med. Chem. 18(1), 415-425 (2010).
37. Marson CM. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med. Chem. 9(6), 661-692 (2009).
38. Rajak H, Agarawal A, Parmar P et al. 2,5-Disubstituted-1,3,4-oxadiazoles/ thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 21(19), 5735-5738 (2011).
39. Zhang YJ, Feng JH, Liu CX et al. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors. Bioorg. Med. Chem. Lett. 18(5), 1761-1772 (2010).
40. Canzoneri JC, Chen PC, Oyelere AK. Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide. Bioorg. Med. Chem. Lett. 19(23), 6588-6590 (2009).
41. Butler KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr. Pharm. Design 14(6), 505-528 (2008). (Pubitemid 351516876)
42. Shultz MD, Cao XY, Chen CH et al. Optimiz-ation of the in vitro cardiac safety of hydrox-amate-based histone deacetylase inhibitors. J. Med. Chem. 54(13), 4752-4772 (2011).
43. Mwakwari SC, Guerrant W, Patil V et al. Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton. J. Med. Chem. 53(16), 6100-6111 (2010).
44. Rotili D, Simonetti G, Savarino A, Palamara AT, Migliaccio AR, Mai A. Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and b-hemoglobinopathies. Curr. Top. Med. Chem. 9(3), 272-291 (2009).
45. Gilbert J, Baker SD, Bowling MK et al. A Phase 1 dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 7(8), 2292-2300 (2001). (Pubitemid 32751627)
46. Sandor V, Bakke S, Robey RW et al. Phase 1 trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8(3), 718-728 (2002). (Pubitemid 34742100)
47. Porcu P, Wong HK. We should have a dream: unlocking the workings of the genome in cutaneous T-cell lymphomas. Clin. Lymphoma Myeloma 9(6), 409-411 (2009).
48. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247-1252 (2007). (Pubitemid 350106355)
49. Olsen EA, Kim YH, Kuzel TM et al. Phase 2B multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(21), 3109-3115 (2007). (Pubitemid 47218059)
50. Meyer N, Paul C, Misery L. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat. Acta Dermatol Venereologica 90(1), 12-17 (2010).
51. Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1), 31-39 (2007). (Pubitemid 46053039)
52. Piekarz RL, Frye R, Turner M et al. Phase 2 multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27(32), 5410-5417 (2009).
53. Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28(29), 4485-4491 (2010).
54. Vansteenkiste J, Van Cutsem E, Dumez H et al. Early Phase 2 trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest. N. Drugs 26(5), 483-488 (2008).
55. Woyach JA, Kloos RT, Ringel MD et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J. Clin. Endocrinol. Metab. 94(1), 164-170 (2009).
56. Stadler WM, Margolin K, Ferber S, Mcculloch W, Thompson JA. A Phase 2 study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 5(1), 57-60 (2006).
57. Whitehead R, Rankin C, Hoff P et al. Phase 2 trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest oncology group study (S0336). Invest. New Drugs 27(5), 469-475 (2009).
58. Martinet N, Bertrand P. Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manage. Res. 3(1), 117-141 (2011).
59. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J. Clin. Oncol. 25(22), 3362-3371 (2007). (Pubitemid 47325624)
60. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin. Invest. Drugs 16(5), 659-678 (2007). (Pubitemid 46729100)
61. Tan J, Cang S, Ma Y, Petrillo R, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3(1), 5 (2010).
62. Federico M, Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J. Biomed. Biotechnol. (2011).
63. Wolbrette D. Drugs that cause torsades de pointes and increase the risk of sudden cardiac death. Curr. Cardiol. Rep. 6(5), 379-384 (2004). (Pubitemid 39232727)
64. Bates SE, Rosing DR, Fojo T, Piekarz RL. Challenges of evaluating the cardiac effects of anticancer agents. Clin. Cancer Res. 12(13), 3871-3874 (2006). (Pubitemid 44078067)
65. Shah MH, Binkley P, Chan K et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 12(13), 3997-4003 (2006). (Pubitemid 44078086)
66. Ponte ML, Keller GA, Girolamo GD. Mechanisms of drug induced QT interval prolongation.Curr. Drug Saf. 5(1), 44-53 (2010).
67. Hoffmann P, Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods 53(2), 87-105 (2006).
68. Guo J, Li X, Shallow H et al. Involvement of caveolin in probucol-induced reduction in hERG plasma-membrane expression. Mol. Pharmacol. 79(5), 806-813 (2011).
69. Perrin MJ, Subbiah RN, Vandenberg JI, Hill AP. Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction. Prog. Biophys. Mol. Biol. 98(2-3), 137-148. (2008).
70. Lacerda AE, Kuryshev YA, Chen Y et al. Alfuzosin delays cardiac repolarization by a novel mechanism. J. Pharmacol. Exp. Ther. 324(2), 427-433 (2008). (Pubitemid 351185830)
71. Kupershmidt S, Yang T, Anderson ME et al. Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. Circulation Res. 84(2), 146-152 (1999). (Pubitemid 29070109)
72. Abbott GW, Sesti F, Splawski I et al. MiRP1 forms IKr potassium channels withHERG and is associated with cardiac arrhythmia. Cell 97(2), 175-187 (1999).
73. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the hminK gene cause long QT syndrome and suppress lKs function. Nat. Genet. 17(3), 338-340 (1997). (Pubitemid 27476001)
74. Munster PN, Rubin EH, Van Belle S et al. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin. Cancer Res. 15(22), 7077-7084 (2009).
75. Montgomery RL, Davis CA, Potthoff MJ et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 21(14), 1790-1802 (2007). (Pubitemid 47076478)
76. Kerr JS, Galloway S, Lagrutta A et al. Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Int. J. Toxicol. 29(1), 3-19 (2010).
77. Razak ARA, Hotte SJ, Siu LL et al. Phase 1 clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br. J. Cancer 104(5), 756-762 (2011).
78. Wang H, Yu N, Chen D et al. Discovery of (2E)-3-{2-Butyl-1-[2- (diethylamino)ethyl]- 1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J. Med. Chem. 54(13), 4694-4720 (2011).
79. Brana I, Tabernero J. Cardiotoxicity. Annu. Oncol. 21(Suppl. 7), vii173-vii179 (2010).
80. Roden DM. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350(10), 1013-1022 (2004). (Pubitemid 38269278)
81. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J. Clin. Oncol. 21(19), 3609-3615 (2003). (Pubitemid 46594053)
82. Ederhy S, Cohen A, Dufaitre G et al. QT interval prolongation among patients treated with angiogenesis inhibitors. Targeted Oncol. 4(2), 89-97 (2009).
83. De Ponti F, Poluzzi E, Montanaro N, Ferguson J. QTc and psychotropic drugs. Lancet 356(9223), 75-76 (2000). (Pubitemid 30417008)
84. De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur. J. Clin. Pharmacol. 57(3), 185-209 (2001). (Pubitemid 32662464)
85. Hann D, Winter K, Jacobsen P. Measurement of depressive symptoms in cancer patients: Evaluation of the center for epidemiological studies depression scale (Ces-d). J. Psychosomatic Res. 46(5), 437-443 (1999). (Pubitemid 29277215)
86. Ijaz AK. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am. J. Med. 112(1), 58-66 (2002).
87. Sawyers C. Targeted cancer therapy. Nature 432(7015), 294-297 (2004). (Pubitemid 39551656)
88. Khan N, Jeffers M, Kumar S et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409(2), 581-589 (2008). (Pubitemid 351184977)
89. Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett. 280(2), 211-221 (2009).
90. Jones P, Altamura S, De Francesco A et al. Probing the elusive catalytic activity of vertebrate Class 2a histone deacetylases. Bioorg. Med. Chem. Lett. 18(6), 1814-1819 (2008). (Pubitemid 351391847)
91. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 280(2), 168-176 (2009).
92. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDACI in hormone refractory prostate cancer. Prostate 59(2), 177-189 (2004). (Pubitemid 38481229)
93. Barlesi F, Giaccone G, Gallegos-Ruiz MI et al. Global histone modifications predict prognosis of resected non-small-cell lung cancer. J. Clin. Oncol. 25(28), 4358-4364 (2007). (Pubitemid 350013840)
94. Huang BH, Laban M, Leung CHW et al. Inhibition of histone deacetylase 2 increases apoptosis and p21(Cip1/WAF1) expression, independent of histone deacetylase 1. Cell Death Differ. 12(4), 395-404 (2005). (Pubitemid 40520691)
95. Fournel M, Bonfils C, Hou Y et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 7(4), 759-768 (2008). (Pubitemid 351551029)
96. Henning SW, Doblhofer R, Kohlhof H et al. Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor. Eur. J. Cancer Suppl. 8(7), 61 (2010).
97. Ryan QC, Headlee D, Acharya M et al. Phase 1 and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23(17), 3912-3922 (2005). (Pubitemid 46218694)
98. Kummar S, Gutierrez M, Gardner ER et al. Phase 1 trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin. Cancer Res. 13(18), 5411-5417 (2007). (Pubitemid 47510368)
99. Gore L, Rothenberg ML, O'Bryant CL et al. A Phase 1 and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 14(14), 4517-4525 (2008).
100. Gojo I, Jiemjit A, Trepel JB et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109(7), 2781-2790 (2007). (Pubitemid 46482071)
101. Hauschild A, Trefzer U, Garbe C et al. Multicenter Phase 2 trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2- aminophenyl)-carbamoyl]- benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res. 18(4), 274-278 (2008).
102. Blum KA, Advani A, Fernandez L et al. Phase 2 study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br. J. Haematol. 147(4), 507-514 (2009).
103. Siu LL, Pili R, Duran I et al. Phase 1 study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J. Clin. Oncol. 26(12), 1940-1947 (2008).
104. Cole KE, Dowling DP, Boone MA, Phillips AJ, Christianson DW. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J. Am. Chem. Soc. 133(32), 12474-12477 (2011).
105. Boyault C, Sadoul K, Pabion M, Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 26(37), 5468-5476 (2007). (Pubitemid 47255928)
106. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett. 277(1), 8-21 (2009).
107. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J. Biomed. Biotechnol. doi:10.1155/2011/875824 (2011).
108. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100(8), 4389-4394 (2003). (Pubitemid 36457739)
109. Auzzas L, Larsson A, Matera R et al. Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity. J. Med. Chem. 53(23), 8387-8399 (2010).
110. Choi SE, Weerasinghe SVW, Pflum MKH. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. Bioorg. Med. Chem. Lett. 21(20), 6139-6142 (2011).
111. Santo L, Hideshima T, Kung AL et al. Selective inhibition of HDAC6 with a new prototype inhibitor (ACY-1215) overcomes bortezomib resistance in multiple myeloma (MM). ASH Annu. Meet. Abstracts 116(21), 2997- (2010).
112. Waltregny D, Glenisson W, Tran SL et al. Histone deacetylase HDAC8 associates with smooth muscle a-actin and is essential for smooth muscle cell contractility. FASEB J. 19(8), 966-968 (2005). (Pubitemid 40827719)
113. Oehme I, Deubzer HE, Wegener D et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin. Cancer Res. 15(1), 91-99 (2009).
114. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI- 34051 induces apoptosis in T-cell lymphomas. Leukemia 22(5), 1026-1034 (2008). (Pubitemid 351689885)
115. Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg. Med. Chem. Lett. 17(10), 2874-2878 (2007). (Pubitemid 46636249)
116. Tang WP, Luo TP, Greenberg EF, Bradner JE, Schreiber SL. Discovery of histone deacetylase 8 selective inhibitors. Bioorg. Med. Chem. Lett. 21(9), 2601-2605 (2011).
117. Whitehead L, Dobler MR, Radetich B et al. Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. Bioorg. Med. Chem. 19(15), 4626-4634 (2011).
118. Haberland M, Johnson A, Mokalled MH, Montgomery RL, Olson EN. Genetic dissection of histone deacetylase requirement in tumor cells. Proc. Natl Acad. Sci. USA 106(19), 7751-7755 (2009).
119. Khan N, Jeffers M, Kumar S et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409(2), 581-589 (2008). (Pubitemid 351184977)
120. Shultz M, Fan J, Chen C et al. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 21(16), 4909-4912 (2011).
121. Jehle J, Schweizer PA, Katus HA, Thomas D. Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis. 2, e193 (2011).
122. Mahvi DM, Henry MB, Albertini MR et al. Intratumoral injection of IL-12 plasmid DNA - results of a Phase 1/1B clinical trial. Cancer Gene Ther. 14(8), 717-723 (2007). (Pubitemid 47080365)
123. Botti E, Mercurio C, Spallone G et al. Histone deacetylases as new therapeutical targets for the treatment of non-melanoma skin cancer: results of Phase 1/2a trial with topical DAC060. J. Invest. Dermatol. 131, S46-S46 (2011).
124. De Souza R, Zahedi P, Allen CJ, Piquette- Miller M. Polymeric drug delivery systems for localized cancer chemotherapy. Drug Deliv. 17(6), 365-375 (2010).
125. Government of the United States of America, represented by the Secretary, Department of Health and Human Services, topical formulations of histone deacetylase inhibitors and methods using the same, US20080292616A1 (2008).
126. Virasi M, Thaler F, Abate A et al. Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors. J. Med. Chem. 54(8), 3051-3064 (2011).
127. Thaler F, Colombo A, Mai A et al. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors. J. Med. Chem. 53(2), 822-839 (2009).
128. Bradner J, Greenberg E, Ponduru S et al. A soft-drug histone deacetylase inhibitor for cutaneous T-cell lymphoma. ASH Annu. Meet. Abstracts 110(11), 800 (2007).
129. Tong W, Stevenson W, Cortes J et al. In vitro and in vivo anti-leukemia activity of CHR- 2845, a cell-targeted HDAC inhibitor for use in monocytic leukemia. ASCO Meet. Abstracts 27(15S), e14579 (2009).
130. Ossenkoppele G, Lowenberg B, Zachee P et al. CHR-2845, a monocyte/macrophage targeted histone deacetylase inhibitor in a first in man clinical trial in subjects with advanced haematological malignancies. ASH Annu. Meet. Abstracts 116(21), 3279 (2010).
131. Hoepelman IM, Schneider MME. Azithromycin - the first of the tissue-selective azalides. Int. J. Antimicrob. Agents 5(3), 145-167 (1995).
132. Ono T, Kashimura M, Suzuki K et al. In vitro and in vivo antibacterial activities of the tricyclic ketolide TE-802 and its analogs. J. Antibiot. 57(8), 518-527 (2004). (Pubitemid 39255676)
133. Togami K, Chono S, Seki T, Morimoto K. Distribution characteristics of telithromycin, a novel ketolide antimicrobial agent applied for treatment of respiratory infection, in lung epithelial lining fluid and alveolar macrophages. Drug Metab. Pharmacokinet. 24(5), 411-417 (2009).
134. Di Paolo A, Barbara C, Chella A, Angeletti CA, Del Tacca M. Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacol. Res. 46(6), 545-550 (2002). (Pubitemid 35439167)
135. Patel KB, Xuan DW, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40(10), 2375-2379 (1996). (Pubitemid 26328049)
136. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin. Pharmacokinet. 37(5), 385-398 (1999).
137. Oyelere AK, Chen PC, Guerrant W et al. Non-peptide macrocyclic histone deacetylase inhibitors. J. Med. Chem. 52(2), 456-468 (2009).
138. Bottomley MJ, Lo Surdo P, Di Giovine P et al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem. 283(39), 26694-26704 (2008).
139. Schuetz A, Min J, Allali-Hassani A et al. Human HDAC7 harbors a Class 2a histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem. 283(17), 11355-11363 (2008).
140. Wang HS, Dymock BW. New patented histone deacetylase inhibitors. Expert Opin. Ther. Patents 19(12), 1727-1757 (2009).
141. Lin JH. Tissue distribution and pharmacodynamics: a complicated relationship. Curr. Drug Metab. 7(1), 39-65 (2006).
142. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771-782 (2008).
143. Schilsky RL. Personalized medicine in oncology: the future is now. Nat. Rev. Drug Discov. 9(5), 363-366 (2010).
144. Vucic EA, Brown CJ, Lam WL. Epigenetics of cancer progression. Pharmacogenomics 9(2), 215-234 (2008). (Pubitemid 351575091)
145. Ruthenburg AJ, Li HT, Milne TA et al. Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions. Cell 145(5), 692-706 (2011).